glp-1 receptor agonists for weight loss PDB-101: Molecule of the Month: Beyond Weight Loss: Other Benefits
Description
Liraglutide is classified as a glucagon-like peptide-1 (GLP-1) receptor agonist
37% achieved 20% weight loss, indicating a magnitude of effect greater than that typically observed with earlier pharmacotherapies for obesity
In 2022, total Medicare expenditures on the GLP-1/GIP agonists were $5.7 billion
Hine J, Paterson H, Abrol E, et al
This has broadened the range of individuals who use weight-loss drugs and has boosted the growth of the weight-loss drug market
Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression
